KURA Logo

Kura Oncology, Inc. (KURA) 

NASDAQ
Market Cap
$1.37B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
600 of 776
Rank in Industry
324 of 433

Largest Insider Buys in Sector

KURA Stock Price History Chart

KURA Stock Performance

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable …

Insider Activity of Kura Oncology, Inc.

Over the last 12 months, insiders at Kura Oncology, Inc. have bought $0 and sold $2.1M worth of Kura Oncology, Inc. stock.

On average, over the past 5 years, insiders at Kura Oncology, Inc. have bought $575,000 and sold $7M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 50,000 shares for transaction amount of $575,000 was made by Malley Thomas (director) on 2023‑06‑16.

List of Insider Buy and Sell Transactions, Kura Oncology, Inc.

2024-05-20SaleChief Legal Officer
2,615
0.0034%
$22.15$57,916-9.14%
2024-01-30SaleChief Medical Officer
4,825
0.0067%
$21.55$103,980-2.17%
2024-01-29SaleChief Legal Officer
2,053
0.0027%
$17.80$36,544+10.16%
2024-01-29SaleSVP, Finance & Accounting
2,318
0.003%
$17.80$41,262+10.16%
2024-01-29SaleChief Medical Officer
7,158
0.0093%
$17.80$127,416+10.16%
2024-01-29SaleChief Operating Officer
1,496
0.0019%
$17.80$26,630+10.16%
2024-01-24SalePresident and CEO
84,107
0.1166%
$20.23$1.7M+3.94%
2023-06-16Purchasedirector
50,000
0.0781%
$11.50$575,000+13.75%
2023-01-27SaleChief Medical Officer
9,225
0.0138%
$13.88$128,033-19.28%
2023-01-27SaleChief Operating Officer
1,821
0.0027%
$13.89$25,294-19.28%
2023-01-27SaleCCO & Chief Strategy Officer
1,906
0.0029%
$13.89$26,474-19.28%
2023-01-27SaleSVP, Finance & Accounting
1,548
0.0023%
$13.89$21,502-19.28%
2021-03-15SaleChief Operating Officer
6,250
0.0095%
$29.43$183,951-36.81%
2020-12-15SaleChief Operating Officer
9,375
0.0161%
$40.60$380,667-46.25%
2020-11-10SaleChief Operating Officer
6,250
0.0107%
$39.43$246,438-37.05%
2020-10-08SalePresident and CEO
157,106
0.2753%
$34.00$5.34M-16.38%
2020-10-07SalePresident and CEO
99,900
0.1621%
$32.00$3.2M-17.58%
2020-10-06SalePresident and CEO
100
0.0002%
$32.00$3,200-10.97%
2020-09-15SaleChief Operating Officer
6,250
0.0115%
$29.43$183,938+1.34%
2020-09-14SalePresident and CEO
196,980
0.3454%
$28.82$5.68M-1.48%

Insider Historical Profitability

8.18%
EcoR1 Capital Fund Qualified, L.P.10 percent owner
4408097
5.7521%
$17.8581+14.44%
Malley Thomasdirector
139557
0.1821%
$17.8520<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Suvretta Capital Management, LLC$150.8M9.287.07M+1.78%+$2.63M6.37
BlackRock$147.16M9.066.9M-5.69%-$8.88M<0.01
Ecor1 Capital Llc$123.86M7.625.81M0%+$00.87
Deerfield Management$115.43M7.15.41M+1.86%+$2.11M0.28
Bvf Inc Il$102.09M6.284.79M-35.09%-$55.18M0.75
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.